Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Energy Select Sector SPDR Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Energy Select Sector SPDR Fund trades at $55.82. Which is the better fit depends on your goals.
| ACAD | XLE | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $62.57 |
52-Week Low | $20.06 | $42.12 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XLE trades at $53.13, down 0.17% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF has gained 21% year-to-date, ranking among top-performing sector SPDRs according to ETF Trends on July 2, 2026. Recent news highlights oil price volatility and geopolitical developments affecting energy sector performance, while a dividend of $0.38 is scheduled for June 2026.
Outlook remains mixed with technical weakness offset by strong YTD performance. Investment opportunity exists for investors seeking energy sector exposure amid ongoing oil market volatility, though risks include geopolitical tensions and potential Federal Reserve rate hikes that could pressure the sector. The neutral oscillator reading suggests potential for near-term stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
